Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIKET: Neurocircuitry of Irritability in MDD Treated with Ketamine
NCT05046184Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), sponsored by UT Southwestern Medical Center. Started May 2022; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05046184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046184.